Rahul Purwar

Indian Institute of Technology Bombay — India

Medicine · Health Sciences

20h-index1.9kcitations94works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(29), Cutaneous lymphoproliferative disorders research(19), Lymphoma Diagnosis and Treatment(14), T-cell and Retrovirus Studies(13), Immune Cell Function and Interaction(10)

Publications93 total

Proteomic dysregulation was investigated in a human T-cell lymphoma model to explore IL-17A-mediated pathogenesis. Label-free quantification was employed to determine fold changes in protein abundance between IL-17A-treated and untreated HuT 78 cells. Specifically, HuT 78 cells were treated with cytokine IL-17A (100 ng/ml), followed by protein extraction using the Trizol-chloroform method. The extracted proteins were digested with 1 microgram of MS-grade trypsin, and the resulting peptide samples were injected into a Thermo Scientific Q-Exactive Plus mass spectrometer, coupled with an EasyNLC HPLC autosampler and C18 PepMap trap column. Mass spectra were analyzed using the Thermo Scientific Proteome Discoverer platform (version 2.2), employing Mascot and SequestHT as search engines. Standard workflows for discovery proteomics were applied. This dataset successfully modeled IL-17A-driven inflammation in HuT 78 cells, revealing numerous dysregulated signaling pathways, which may provide potential targets for novel therapeutic strategies
Open MIND·2026
MassIVE MSV000100817 - IL-17A treated HuT 78 proteomics
2026Open Access
Early use of talicabtagene autoleucel in r/r B-acute lymphoblastic leukemia is cost-effective: Improved efficacy, reduced toxicity and healthcare resource utilization support affordable access
Blood·2025Open Access
Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India.
Blood·2025Open Access
A multicentre Phase I clinical trial demonstrates manufacturing feasibility, safety and activity of novel humanized BCMA-directed CAR-T cell therapy.
Blood·2025
IL-17–Induced CD70 expression promotes T-cell suppression in DLBCL: Implications for immune escape and T-cell exhaustion
Blood·2025Open Access
Molecular Profiling of Belumosudil-Treated IOMM-Lee Meningioma Cells Reveals Repurposing Potential via Enhanced Oxidative Phosphorylation and ROS-Mediated Cell Death
Journal of Proteome Research·2025· 1 cited
Figure S5 from IL-9 Promotes Migratory Dissemination of Malignant T Cells by Activating the HIF-1α–Cofilin-1 Axis in Cutaneous T-cell Lymphoma
2025Open Access
Figure S4 from IL-9 Promotes Migratory Dissemination of Malignant T Cells by Activating the HIF-1α–Cofilin-1 Axis in Cutaneous T-cell Lymphoma
2025Open Access
Data from IL-9 Promotes Migratory Dissemination of Malignant T Cells by Activating the HIF-1α–Cofilin-1 Axis in Cutaneous T-cell Lymphoma
2025Open Access
Supplementary Figure Legends from IL-9 Promotes Migratory Dissemination of Malignant T Cells by Activating the HIF-1α–Cofilin-1 Axis in Cutaneous T-cell Lymphoma
2025Open Access
Figure S1 from IL-9 Promotes Migratory Dissemination of Malignant T Cells by Activating the HIF-1α–Cofilin-1 Axis in Cutaneous T-cell Lymphoma
2025Open Access
Figure S2 from IL-9 Promotes Migratory Dissemination of Malignant T Cells by Activating the HIF-1α–Cofilin-1 Axis in Cutaneous T-cell Lymphoma
2025Open Access
Table S1 from IL-9 Promotes Migratory Dissemination of Malignant T Cells by Activating the HIF-1α–Cofilin-1 Axis in Cutaneous T-cell Lymphoma
2025Open Access
Figure S6 from IL-9 Promotes Migratory Dissemination of Malignant T Cells by Activating the HIF-1α–Cofilin-1 Axis in Cutaneous T-cell Lymphoma
2025Open Access
Table S2 from IL-9 Promotes Migratory Dissemination of Malignant T Cells by Activating the HIF-1α–Cofilin-1 Axis in Cutaneous T-cell Lymphoma
2025Open Access
Figure S3 from IL-9 Promotes Migratory Dissemination of Malignant T Cells by Activating the HIF-1α–Cofilin-1 Axis in Cutaneous T-cell Lymphoma
2025Open Access
CT-1293: Extended Immune-Cell Monitoring After Chimeric Antigen Receptor T-Cell (CAR-T) Infusion in B-Acute Lymphoblastic Leukemia (B-ALL) Using High-Dimensional Flow Cytometry: A Single-Center 6-Month Experience From North India
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: CT-1080 Incidence, Clinical Characteristics, and Risk Factors of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IECHS) in Patients Treated With Talicabtagene Autoleucel (Humanized Anti-CD19 CAR-T)
Clinical Lymphoma Myeloma & Leukemia·2025
CT-1080: Incidence, Clinical Characteristics, and Risk Factors of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS) in Patients Treated With Talicabtagene Autoleucel (Humanized Anti-CD19 CAR-T)
Clinical Lymphoma Myeloma & Leukemia·2025
page 1 of 5Next →

Frequent Co-authors

Atharva Karulkar(23), Sweety Asija(13), Ankesh Kumar Jaiswal(12), Juber Pendhari(12), Sushant Kumar(11), Nirali N. Shah(11), Manju Sengar(11), Alka Dwivedi(10), Hasmukh Jain(10), Shreshtha Shah(10), Afrin Firfiray(10), Aalia Khan(9), Gaurav Narula(9), Bhausaheb Bagal(9), Thomas Werfel(8), Smrithi Ravikumar(8), Lingaraj Nayak(8), Miriam Wittmann(7), Prashant Tembhare(7), Devanshi Kalra(7)